# CNTRL

Source: https://onco.cc/targets/cntrl/  
OnCo record `cntrl` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CNTRL (Centriolin) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Nasopharyngeal carcinoma, Cutaneous squamous cell carcinoma and 1 more.

## Summary

Involved in cell cycle progression and cytokinesis. During the late steps of cytokinesis, anchors exocyst and SNARE complexes at the midbody, thereby allowing secretory vesicle-mediated abscission.

Open Targets scores its association with cancer at 0.67 (direct and indirect evidence; datatypes literature 0.71, affected pathway 0.94, genetic association 0.00, somatic mutation 0.45). IntOGen calls it a driver in 3 cohorts (1 activating, 2 loss-of-function), covering Cutaneous Squamous Cell Carcinoma, Nasopharyngeal Carcinoma, Thymoma.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: centriolin; Centriolin; CEP1; CEP110
- Tags: cancer-genes-wave
- Symbol: CNTRL
- Class: tumor-suppressor
- Biology: Involved in cell cycle progression and cytokinesis. During the late steps of cytokinesis, anchors exocyst and SNARE complexes at the midbody, thereby allowing secretory vesicle-mediated abscission. Location: Cytoplasm, cytoskeleton, microtubule organizing center, centrosome; Midbody, Midbody ring (UniProt). Locus 9q33.2 (HGNC).
- Where found: Leukaemia: Open Targets association 0.57 with leukaemia (MONDO_0005059); Nasopharyngeal carcinoma: IntOGen driver in 1 cohort (NPC); Cutaneous squamous cell carcinoma: IntOGen driver in 1 cohort (CSCC); Thymoma: IntOGen driver in 1 cohort (THYM)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 1 cohort; IntOGen calls it a loss-of-function (LoF) driver in 2 cohorts; UniProt disease notes describe a translocation or gene fusion involving the gene. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:1858: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1858
- UniProt Q7Z7A1: https://www.uniprot.org/uniprotkb/Q7Z7A1/entry
- NCBI Gene 11064: https://www.ncbi.nlm.nih.gov/gene/11064
- Ensembl ENSG00000119397: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000119397

## Connected records

- collections: [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Cutaneous squamous cell carcinoma](https://onco.cc/cancers/cutaneous-scc/), [Leukaemia (all types)](https://onco.cc/cancers/leukaemia/), [Nasopharyngeal carcinoma](https://onco.cc/cancers/nasopharyngeal/), [Thymoma (WHO types A, AB, B1, B2 and B3)](https://onco.cc/cancers/thymoma/)

---
JSON: https://onco.cc/api/v1/entities/cntrl.json